Clinical review: The liver in sepsis

Critical Care

Volumn 16, Issue 5, 2012, Pages

  Nesseler, Nicolas ^a,b   Launey, Yoann ^a,b   Aninat, Caroline ^a,b   Morel, Fabrice ^a,b   Mallédant, Yannick ^a,b   Seguin, Philippe ^a,b  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTASIS; DISEASE SEVERITY; HEPATITIS; HUMAN; HYPOXIC HEPATITIS; INCIDENCE; JAUNDICE; LIVER DYSFUNCTION; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS; LIVER; LIVER DISEASE; METABOLISM;

CYTOKINE;

CYTOKINES; HUMANS; LIVER; LIVER DISEASES; SEPSIS;

EID: 84868685047     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11381     Document Type: Review

References (72)

1. Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F, Tamayo L, Collado J, García-Labattut A, Carriedo D, Valledor M, De Frutos M, López M, Caballero A, Guerra J, Alvarez B, Mayo A, Villar J. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 2008, 12:R158. 10.1186/cc7157, 2646323, 19091069.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
3. Dhainaut JF, Marin N, Mignon A, Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001, 29:S42-47.
4. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BLJ, Platt R. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997, 278:234-240. 10.1001/jama.1997.03550030074038, 9218672.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
6. Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, doubleblind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004, 32:1-12. 10.1097/01.CCM.0000105118.66983.19, 14707554.
7. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
8. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Kitzberger R, Warszawska J, Holzinger U, Schenk P, Madl C. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009, 35:1397-1405. 10.1007/s00134-009-1508-2, 19506833.
9. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004, 30:580-588.
10. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G, Bernard GR, . for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003, 31:834-840. 10.1097/01.CCM.0000051515.56179.E1, 12626993, for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
11. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23:1638-1652. 10.1097/00003246-199510000-00007, 7587228.
12. Sakka SG. Assessing liver function. Curr Opin Crit Care 2007, 13:207-214. 10.1097/MCC.0b013e328012b268, 17327744.
13. Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama S. Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med 2001, 29:1159-1163. 10.1097/00003246-200106000-00014, 11395594.
14. Kortgen A, Paxian M, Werth M, Recknagel P, Rauchfuss F, Lupp A, Krenn CG, Müller D, Claus RA, Reinhart K, Settmacher U, Bauer M. Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. Shock 2009, 32:358-365. 10.1097/SHK.0b013e31819d8204, 19197231.
15. Stehr A, Ploner F, Traeger K, Theisen M, Zuelke C, Radermacher P, Matejovic M. Plasma disappearance of indocyanine green: a marker for excretory liver function?. Intensive Care Med 2005, 31:1719-1722. 10.1007/s00134-005-2826-7, 16231068.
16. Hebert PC, Drummond AJ, Singer J, Bernard GR, Russell JA. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 1993, 104:230-235. 10.1378/chest.104.1.230, 8325076.
17. Abraham E, Laterre P, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341. 10.1056/NEJMoa050935, 16192478.
18. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887. 10.1056/NEJMoa067373, 18305265.
19. Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. Am J Physiol 1985, 249:G549-556.
20. Vary TC, Kimball SR. Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol 1992, 262:C445-452.
21. Casteleijn E, Kuiper J, Van Rooij HC, Kamps JA, Koster JF, Van Berkel TJ. Endotoxin stimulates glycogenolysis in the liver by means of intercellular communication. J Biol Chem 1988, 263:6953-6955.
22. Meinz H, Lacy DB, Ejiofor J, McGuinness OP. Alterations in hepatic gluconeogenic amino acid uptake and gluconeogenesis in the endotoxin treated conscious dog. Shock 1998, 9:296-303. 10.1097/00024382-199804000-00010, 9565259.
23. Harbrecht BG, Frye RF, Zenati MS, Branch RA, Peitzman AB. Cytochrome P-450 activity is differentially altered in severely injured patients. Crit Care Med 2005, 33:541-546. 10.1097/01.CCM.0000155989.54344.E0, 15753745.
24. Jacob A, Zhou M, Wu R, Wang P. The role of hepatic cytochrome P-450 in sepsis. Int J Clin Exp Med 2009, 2:203-211. 2770183, 19918313.
25. Katz S, Jimenez MA, Lehmkuhler WE, Grosfeld JL. Liver bacterial clearance following hepatic artery ligation and portacaval shunt. J Surg Res 1991, 51:267-270. 10.1016/0022-4804(91)90105-U, 1881140.
26. Nakatani Y, Fukui H, Kitano H, Nagamoto I, Tsujimoto T, Kuriyama S, Kikuchi E, Hoppou K, Tsujii T. Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver 2001, 21:64-70. 10.1034/j.1600-0676.2001.210110.x, 11169075.
27. Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowry SF. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 1990, 85:1896-1904. 10.1172/JCI114651, 296656, 2347917.
28. Migita K, Abiru S, Nakamura M, Komori A, Yoshida Y, Yokoyama T, Daikoku M, Ueki T, Takii Y, Yano K, Yastuhashi H, Eguchi K, Ishibashi H. Lipopolysaccharide signaling induces serum amyloid A (SAA) synthesis in human hepatocytes in vitro. FEBS Lett 2004, 569:235-239. 10.1016/j.febslet.2004.05.072, 15225640.
29. Aninat C, Seguin P, Descheemaeker P, Morel F, Malledant Y, Guillouzo A. Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med 2008, 36:848-854. 10.1097/CCM.0B013E31816532BE, 18431272.
30. Ring A, Stremmel W. The hepatic microvascular responses to sepsis. Semin Thromb Hemost 2000, 26:589-594. 10.1055/s-2000-13215, 11129415.
31. Koo DJ, Chaudry IH, Wang P. Kupffer cells are responsible for producing inflammatory cytokines and hepatocellular dysfunction during early sepsis. J Surg Res 1999, 83:151-157. 10.1006/jsre.1999.5584, 10329110.
32. Knolle PA, Löser E, Protzer U, Duchmann R, Schmitt E, zum Büschenfelde KH, Rose-John S, Gerken G. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clin Exp Immunol 1997, 107:555-561. 10.1046/j.1365-2249.1997.d01-959.x, 1904597, 9067532.
33. Ayala A, Knotts JB, Ertèl W, Perrin MM, Morrison MH, Chaudry IH. Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg 1993, 128:89-94. discussion 94-95, 10.1001/archsurg.1993.01420130101015, 8418786.
34. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, Daynes RA, Kushner JP, Li D, Ward DM, Kaplan J. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010, 120:2395-2405. 10.1172/JCI42011, 2898601, 20530874.
35. Huang Y, Yang Y, Tiao M, Kuo H, Huang L, Chuang J. Hepcidin protects against lipopolysaccharide-induced liver injury in a mouse model of obstructive jaundice. Peptides 2012, 35:212-217. 10.1016/j.peptides.2012.03.032, 22504010.
36. Tsutsui H, Matsui K, Kawada N, Hyodo Y, Hayashi N, Okamura H, Higashino K, Nakanishi K. IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997, 159:3961-3967.
37. Bosisio D, Polentarutti N, Sironi M, Bernasconi S, Miyake K, Webb GR, Martin MU, Mantovani A, Muzio M. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 2002, 99:3427-3431. 10.1182/blood.V99.9.3427, 11964313.
38. Wong JM, Billiar TR. Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Adv Pharmacol 1995, 34:155-170.
39. Pastor CM, Losser MR, Payen D. Nitric oxide donor prevents hepatic and systemic perfusion decrease induced by endotoxin in anesthetized rabbits. Hepatology 1995, 22:1547-1553.
40. Sakamoto M, Ueno T, Kin M, Ohira H, Torimura T, Inuzuka S, Sata M, Tanikawa K. Ito cell contraction in response to endothelin-1 and substance P. Hepatology 1993, 18:978-983. 10.1002/hep.1840180432, 7691708.
41. Wang JH, Redmond HP, Watson RW, Condron C, Bouchier-Hayes D. Induction of heat shock protein 72 prevents neutrophil-mediated human endothelial cell necrosis. Arch Surg 1995, 130:1260-1265. 10.1001/archsurg.1995.01430120014002, 7492272.
42. Bauer M, Zhang JX, Bauer I, Clemens MG. ET-1 induced alterations of hepatic microcirculation: sinusoidal and extrasinusoidal sites of action. Am J Physiol 1994, 267:G143-149.
43. Miksa M, Das P, Zhou M, Wu R, Dong W, Ji Y, Goyert SM, Ravikumar TS, Wang P. Pivotal role of the alpha(2A)-adrenoceptor in producing inflammation and organ injury in a rat model of sepsis. PLoS ONE 2009, 4:e5504. 10.1371/journal.pone.0005504, 2677660, 19430535.
44. Zhang F, Wu R, Qiang X, Zhou M, Wang P. Antagonism of alpha2Aadrenoceptor: a novel approach to inhibit inflammatory responses in sepsis. J Mol Med 2010, 88:289-296. 10.1007/s00109-009-0555-z, 2837104, 19894027.
45. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003, 82:392-406. 10.1097/01.md.0000101573.54295.bd, 14663289.
46. Dahn MS, Lange P, Lobdell K, Hans B, Jacobs LA, Mitchell RA. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery 1987, 101:69-80.
47. Henrion J. Hypoxic hepatitis. Liver Int 2011,
48. Raurich JM, Llompart-Pou JA, Ferreruela M, Colomar A, Molina M, Royo C, Ayestarán I, Ibáñez J. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth 2011, 25:50-56. 10.1007/s00540-010-1058-3, 21153035.
49. Gimson AE. Hepatic dysfunction during bacterial sepsis. Intensive Care Med 1987, 13:162-166.
50. Banks JG, Foulis AK, Ledingham IM, Macsween RN. Liver function in septic shock. J Clin Pathol 1982, 35:1249-1252. 10.1136/jcp.35.11.1249, 497938, 7142434.
51. Kramer L, Jordan B, Druml W, Bauer P, Metnitz PGH. Incidence and prognosis of early hepatic dysfunction in critically ill patients--a prospective multicenter study. Crit Care Med 2007, 35:1099-1104. 10.1097/01.CCM.0000259462.97164.A0, 17334250.
52. Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999, 25:686-696. 10.1007/s001340050931, 10470572.
53. Moseley RH. Sepsis and cholestasis. Clin Liver Dis 2004, 8:83-94. 10.1016/S1089-3261(03)00134-X, 15062195.
54. Assimakopoulos SF, Scopa CD, Vagianos CE. Pathophysiology of increased intestinal permeability in obstructive jaundice. World J Gastroenterol 2007, 13:6458-6464. 10.3748/wjg.13.6458, 18161914.
55. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998, 339:1217-1227. 10.1056/NEJM199810223391707, 9780343.
56. Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis 2008, 12:151-172. ix, 10.1016/j.cld.2007.11.002, 18242502.
57. Deeley RG, Westlake C, Cole SPC. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006, 86:849-899. 10.1152/physrev.00035.2005, 16816140.
58. Spirlì C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, Larusso NF, Sonzogni A, Okolicsanyi L, Strazzabosco M. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003, 124:737-753. 10.1053/gast.2003.50100, 12612912.
59. Kamiya S, Nagino M, Kanazawa H, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann Surg 2004, 239:510-517. 10.1097/01.sla.0000118594.23874.89, 1356256, 15024312.
60. Padillo FJ, Muntane J, Montero JL, Briceño J, Miño G, Solorzano G, Sitges-Serra A, Pera-Madrazo C. Effect of internal biliary drainage on plasma levels of endotoxin, cytokines, and C-reactive protein in patients with obstructive jaundice. World J Surg 2002, 26:1328-1332. 10.1007/s00268-002-6232-9, 12297927.
61. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
62. Kubitz R, Wettstein M, Warskulat U, Häussinger D. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 1999, 116:401-410. 10.1016/S0016-5085(99)70138-1, 9922322.
63. Moreno R, Sprung CL, Annane D, Chevret S, Briegel J, Keh D, Singer M, Weiss YG, Payen D, Cuthbertson BH, Vincent J. Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study. Intensive Care Med 2011, 37:1765-1772. 10.1007/s00134-011-2334-x, 21847649.
64. McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B, Ochoa JB, Napolitano L, Cresci G. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009, 33:277-316. 10.1177/0148607109335234, 19398613.
65. Braga M, Gianotti L, Gentilini O, Parisi V, Salis C, Di Carlo V. Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. Crit Care Med 2001, 29:242-248. 10.1097/00003246-200102000-00003, 11246300.
66. Hu Q, Zheng Q. The influence of Enteral Nutrition in postoperative patients with poor liver function. World J Gastroenterol 2003, 9:843-846.
67. Hegazi RA, Wischmeyer PE. Clinical review: optimizing enteral nutrition for critically ill patients - a simple data-driven formula. Crit Care 2011, 15:234. 10.1186/cc10430, 22136305.
68. de Vree JM, Romijn JA, Mok KS, Mathus-Vliegen LM, Stoutenbeek CP, Ostrow JD, Tytgat GN, Sauerwein HP, Oude Elferink RP, Groen AK. Lack of enteral nutrition during critical illness is associated with profound decrements in biliary lipid concentrations. Am J Clin Nutr 1999, 70:70-77.
69. Han MK, Hyzy R. Advances in critical care management of hepatic failure and insufficiency. Crit Care Med 2006, 34:S225-231. 10.1097/01.CCM.0000231882.85350.71, 16917427.
70. Hawker F. Liver dysfunction in critical illness. Anaesth Intensive Care 1991, 19:165-181.
71. Moyer AM, Fridley BL, Jenkins GD, Batzler AJ, Pelleymounter LL, Kalari KR, Ji Y, Chai Y, Nordgren KKS, Weinshilboum RM. Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci 2011, 120:33-41. 10.1093/toxsci/kfq375, 3044203, 21177773.
72. Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci 2011, 121:523-544. 10.1042/CS20110184, 21854363.